Table 3.
Vaccine effectiveness for different time-since-vaccination intervals.
| Days since vaccine dose | VE % (95% CI) | ||||
|---|---|---|---|---|---|
| 0–13 | 14–60 | 61–120 | 121–180 | ≥180 | |
| COVID-19 | |||||
| Unvaccinated | (Ref) | (Ref) | (Ref) | (Ref) | (Ref) |
| 1 dose | |||||
| BNT162b2 | 57.9 (53.7–61.8) | 28.9 (21.3–35.8) | −6.0 (−26.1–10.8) | −34.1 (−50.4 to −19.5) | −5.6 (−21.7–8.4) |
| CoronaVac | 35.1 (32.0–38.0) | −6.3 (−12.5 to −0.5) | 29.3 (−1.7–50.8) | 26.9 (−6.2–49.6) | – |
| 2 doses | |||||
| All BNT162b2 | 58.7 (47.8–67.3) | 39.7 (29.0–48.7) | 20.0 (3.2–33.9) | −7.4 (−20.7–4.4) | 16.5 (8.7–23.6) |
| All CoronaVac | 43.0 (35.2–49.8) | 29.5 (20.1–37.7) | −10.3 (−26.5–3.8) | −35.2 (−63.3 to −12.0) | – |
| 3 doses | |||||
| All BNT162b2 | 78.3 (63.4–87.1) | 39.1 (13.1–57.3) | 24.8 (−2.3–44.7) | 15.6 (−26.8–43.8) | – |
| All CoronaVac | 38.6 (−26.9–70.3) | −1.4 (−57.6–34.8) | 33.9 (−49.4–70.8) | 76.7 (−97.5–97.3) | – |
| B-B-C | 49.3 (−53.3–83.2) | 54.8 (−21.7–83.2) | −13.6 (−118.7–41.0) | 11.0 (−158.8–69.4) | – |
| C-C-B | – | – | – | – | – |
| COVID-19-related hospitalization | |||||
| Unvaccinated | (Ref) | (Ref) | (Ref) | (Ref) | (Ref) |
| 1 dose | |||||
| BNT162b2 | 19.2 (−25.2–47.8) | 45.7 (18.2–64.0) | 0.0 (−64.1–39.1) | −0.4 (−42.7–29.4) | 26.8 (−52.6–64.9) |
| CoronaVac | 7.5 (−13.7–24.7) | −3.4 (−27.3–15.9) | 55.1 (9.7–77.6) | 70.6 (34.7 to −86.8) | – |
| 2 doses | |||||
| All BNT162b2 | 81.0 (35.2–94.4) | 45.5 (−0.2–70.3) | 27.1 (−14.9–53.7) | 30.4 (0.4–51.3) | 33.6 (5.5–53.3) |
| All CoronaVac | 22.0 (−20.0–49.3) | 55.8 (34.9–70.0) | −39.0 (−77.4 to −8.9) | −66.9 (−137.3 to −17.3) | – |
| 3 doses | |||||
| All BNT162b2 | 91.9 (36.4–99.0) | 58.9 (−15.4–85.4) | 46.7 (−11.0–74.4) | 62.0 (−43.3–89.9) | – |
| All CoronaVac | 22.4 (−190.8–79.3) | 69.5 (12.8–89.3) | −91.0 (−745.5–56.8) | – | – |
| B-B-C | – | – | – | – | – |
| C-C-B | – | – | – | – | – |
| Severe COVID-19 | |||||
| Unvaccinated | (Ref) | (Ref) | (Ref) | (Ref) | (Ref) |
| 1 dose | |||||
| BNT162b2 | 10.9 (−40.6–43.6) | 47.8 (15.0–68.0) | 23.2 (−32.7–55.6) | −6.9 (−55.4–26.5) | 20.2 (−80.3–64.7) |
| CoronaVac | 3.0 (−20.2–21.7) | −6.5 (−35.6–16.3) | 39.8 (−22.7–70.5) | 65.7 (22.0–84.9) | – |
| 2 doses | |||||
| All BNT162b2 | 70.5 (−9.4–92.1) | 67.3 (34.1–83.8) | 48.0 (13.4–68.8) | 21.4 (−13.6–45.7) | 29.2 (−4.9–52.2) |
| All CoronaVac | 6.5 (−53.4–43.0) | 57.6 (32.8–73.2) | −42.5 (−84.6 to −10.1) | −48.8 (−120.0 to −0.7) | – |
| 3 doses | |||||
| All BNT162b2 | – | 73.3 (20.5–91.0) | 75.9 (43.6–89.7) | 76.2 (−37.9–95.9) | – |
| All CoronaVac | 58.8 (−58.5–89.3) | 75.7 (23.7–92.3) | −33.8 (−463.6–68.2) | – | – |
| B-B-C | – | – | – | – | – |
| C-C-B | – | – | – | – | – |
OR: odds ratio, VE: vaccine effectiveness, CI: confidence interval, B-B-C: two doses of BNT162b2 followed by CoronaVac, C-C-B: two doses of CoronaVac followed by BNT162b2.